ArriVent BioPharma, Inc. Common Stock (AVBP) Live Share Price, Invest From India

ArriVent BioPharma, Inc. Common Stock Stock Performance

as on April 18, 2026 at 6:59 am IST

Day's Low
Day's High
$29.58
Day's Price Range
$30.72
$29.51
-0.24%
Downside
4.10%
Upside
52 Week's Low
52 Week's High
$16.10
52-Week Price Range
$30.72
$29.51
45.44%
Downside
4.10%
Upside

ArriVent BioPharma, Inc. Common Stock share price movements today

Previous Close: $29.61
Open: $30.32
Volume: 369.0K
Day's Low - High: $29.58 - $30.72
52 Week Low - High: $16.10 - $30.72

ArriVent BioPharma, Inc. Common Stock Historical Returns

1 Month Return: + 29.94 %
3 Month Return: + 42.09 %
1 Year Return: + 63.4 %
3 Year Return: 0 %
5 Year Return: 0 %

ArriVent BioPharma, Inc. Common Stock Stock Fundamentals & Key Indicators

Check ArriVent BioPharma, Inc. Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.3B

EPS (TTM)

-4.2838

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-58.88%

ArriVent BioPharma, Inc. Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of ArriVent BioPharma, Inc. Common Stock with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
ArriVent BioPharma, Inc. Common Stock	BUY	$1.3B	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$41.3B	122.97%	133.47	8.45%
Vertex Pharmaceuticals Inc	BUY	$110.8B	101.1%	28.42	32.94%
BeiGene, Ltd.	NA	$37.2B	NA	131.65	5.37%
Regeneron Pharmaceuticals Inc	BUY	$78.9B	49.34%	17.98	31.41%

Stock Returns calculator for ArriVent BioPharma, Inc. Common Stock Stock including INR - Dollar returns

The ArriVent BioPharma, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

ArriVent BioPharma, Inc. Common Stock investment value today

Current value as on today

₹1,76,230

Returns

₹76,230

(+76.23%)

Returns from ArriVent BioPharma, Inc. Common Stock Stock

₹62,679 (+62.68%)

Dollar Impact

₹13,551 (+13.55%)

Analyst Recommendation on ArriVent BioPharma, Inc. Common Stock Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for ArriVent BioPharma, Inc. Common Stock. Average target price of $41.1

ArriVent BioPharma, Inc. Common Stock Share Price Target

Get share price movements and forecasts by analysts on ArriVent BioPharma, Inc. Common Stock.

What analysts predicted

28.2%UPSIDE

Target Price

$41.1

Current Price

$29.51

Analyzed by

11 Analysts

Target

$41.10

ArriVent BioPharma, Inc. Common Stock target price $41.1, a slight upside of 28.2% compared to current price of $29.51. According to 11 analysts rating.

ArriVent BioPharma, Inc. Common Stock Stock’s Investor Sentiment and Interest

Search interest for ArriVent BioPharma, Inc. Common Stock Stock has increased by 175% in the last 30 days, reflecting an upward trend in search activity.

Time period: March 20, 2026 to April 19, 2026

Change:175% versus previous 30 day period

ArriVent BioPharma, Inc. Common Stock Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Income	-16	-23	-20	-25	-24	-23	-66	-33	-38	-38
EBITDA	-16	-23	-20	-25	-24	-23	-66	-31	-34	-38
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-14	-21	-17	-21	-20	-20	-64	-31	-34	-35
Income Tax Expense	-16	-23	-	-	-	-	-	-	-	-
Net Income	-14	-21	-17	-21	-20	-20	-64	-31	-34	-35
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

ArriVent BioPharma, Inc. Common Stock Annual Profit & Loss

All numbers in Millions USD

	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Revenue	-	-	-	-
Gross Profit	-	-	-	-
Operating Income	-36	-74	-94	-177
EBITDA	-36	-74	-80	-177
Interest Expense	-	-	-	-
Depreciation	-	-	-	-
Income Before Tax	-36	-69	-80	-166
Income Tax Expense	-36	-	-80	-
Net Income	-36	-69	-80	-166
Net Profit Margin	0.00%	0.00%	0.00%	0.00%

ArriVent BioPharma, Inc. Common Stock Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-21	-17	-21	-20	-20	-64	-31	-34	-35
Operating Cash Flow	-14	-18	-19	-16	-16	-68	-26	-35	-30
Investing Cash Flow	25	-	-	-	-192	36	13	-50	-71
Financing Cash Flow	-1	185	0	0	0	6	75	86	34
Change in Cash	9	167	-18	-15	-208	-24	62	0	-67

ArriVent BioPharma, Inc. Common Stock Annual Cash Flow

All numbers in Millions USD

	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Net Income	-36	-69	-80	-166
Operating Cash Flow	-43	-55	-70	-160
Investing Cash Flow	-	-	-192	-71
Financing Cash Flow	169	42	186	203
Change in Cash	126	-12	-76	-28

Insights on ArriVent BioPharma, Inc. Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, AVBP has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 1 month, AVBP stock has moved up by 29.7%

About ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Organisation	ArriVent BioPharma, Inc. Common Stock
Headquarters	18 Campus Boulevard, Newtown Square, PA, United States, 19073
Industry	Biotechnology
CEO	Dr. Zhengbin Yao Ph.D.
E-voting on shares	Click here to vote

Key Management of ArriVent BioPharma, Inc. Common Stock

Name	Title
Ms. Robin LaChapelle M.A.	Co-Founder & COO
Ms. Yang Wang Ph.D.	Chief Technology Officer
Dr. James Paul Kastenmayer J.D., Ph.D.	General Counsel & Secretary
Mr. Brent S. Rice	Chief Commercial Officer
Dr. Zhengbin Yao Ph.D.	Co-Founder, Chairman, President & CEO
Dr. Stuart Lutzker M.D., Ph.D.	Co-Founder, President of Research & Development and Director
Mr. Winston Kung M.B.A.	CFO & Treasurer

FAQs

What is ArriVent BioPharma, Inc. Common Stock share price today?

ArriVent BioPharma, Inc. Common Stock share price today is $29.51 as on April 18, 2026 at 1:29 am IST at the close of the market. ArriVent BioPharma, Inc. Common Stock share today touched a day high of $30.72 and a low of $29.58.

What is the 52 week high and 52 week low for ArriVent BioPharma, Inc. Common Stock share?

ArriVent BioPharma, Inc. Common Stock share touched a 52 week high of $30.72 on April 17, 2026 and a 52 week low of $16.1 on August 12, 2025. ArriVent BioPharma, Inc. Common Stock stock price today i.e. April 18, 2026 at 1:29 am IST is closed at $29.51,which is 3.94% down from its 52 week high and 83.29% up from its 52 week low.

What is ArriVent BioPharma, Inc. Common Stock's market capitalisation today?

ArriVent BioPharma, Inc. Common Stock market capitalisation is $0.00T as on April 18, 2026 at 1:29 am IST.

How to invest in ArriVent BioPharma, Inc. Common Stock Stock (AVBP) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for ArriVent BioPharma, Inc. Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in ArriVent BioPharma, Inc. Common Stock Shares that will get you 0.0508 shares as per ArriVent BioPharma, Inc. Common Stock share price of $29.51 per share as on April 18, 2026 at 1:29 am IST.

What is the minimum amount required to buy ArriVent BioPharma, Inc. Common Stock Stock (AVBP) from India?

Indian investors can start investing in ArriVent BioPharma, Inc. Common Stock (AVBP) shares with as little as ₹92.575 or $1 (as of April 19, 2026 at 7:41 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹925.75 in ArriVent BioPharma, Inc. Common Stock stock (as per the Rupee-Dollar exchange rate as on April 19, 2026 at 7:41 am IST). Based on ArriVent BioPharma, Inc. Common Stock share’s latest price of $29.51 as on April 18, 2026 at 1:29 am IST, you will get 0.3389 shares of ArriVent BioPharma, Inc. Common Stock. Learn more about fractional shares .